| Item type |
文献 / Documents(1) |
| 公開日 |
2024-07-18 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1111/1759-7714.15100 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1111/1759-7714.15100 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors |
|
言語 |
en |
| 著者 |
タケウチ, エイジ
コンドウ, ケンスケ
オカノ, ヨシオ
イチハラ, セイヤ
國重, 道大
カドタ, ナオキ
マチダ, ヒサノリ
ハタケヤマ, ノブオ
ナルセ, ケイシ
荻野, 広和
軒原, 浩
篠原, 勉
西岡, 安彦
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: The peripheral blood eosinophil count prior to treatment has potential as a predictive biomarker for a beneficial clinical response to cancer immunotherapies. Therefore, the present study investigated the impact of the eosinophil count on overall survival (OS) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICI).
Methods: We retrospectively reviewed all patients diagnosed with NSCLC and treated with ICI monotherapy between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University.
Results: A total of 166 patients were included. Fifty-five patients had an eosinophil count of less than 100 cells/μL (Eo < 100). Nighty-eight patients had an eosinophil count of 100 cells/μL or more, but less than 500 cells/μL (100 ≤ Eo < 500). Thirteen patients had an eosinophil count of 500 cells/μL or more (Eo ≥500). The median OS of all lung cancer patients was 476 days. The median OS of lung cancer patients with Eo <100, 100 ≤ Eo <500, and Eo ≥500 was 339, 667, and 143 days, respectively. A Kaplan–Meier univariate analysis showed a significant difference in OS between these three groups (p < 0.001). A Cox proportional regression analysis identified 100 ≤ Eo <500 (p = 0.04), ECOG PS score ≥ 2 (p = 0.02), tumor size ≥5 cm (p = 0.02), and PD-L1 ≥ 1% (p = 0.01) as independent predictors of OS.
Conclusion: OS was significantly longer in ICI-treated NSCLC patients with a pretreatment eosinophil count of 100 ≤ Eo <500 than in the other patients and, thus, has potential as a new predictive biomarker. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
biomarker |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
immune checkpoint inhibitors |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
non-small cell lung cancer |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
predictive factor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
pretreatment eosinophils |
| 書誌情報 |
en : Thoracic Cancer
巻 14,
号 30,
p. 3042-3050,
発行日 2023-09-05
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
17597706 |
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
17597714 |
| 出版者 |
|
|
出版者 |
China Lung Oncology Group |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
John Wiley & Sons Australia |
|
言語 |
en |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| EID |
|
|
識別子 |
406942 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
tc_14_30_3042.pdf (899 KB)
.png)
